# OnCo record inavolisib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/inavolisib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "inavolisib" ;
  schema:name "Inavolisib"@en ;
  schema:description "Inavolisib is a PI3K drug that also destroys the mutant protein, approved in 2024 with palbociclib and fulvestrant for PIK3CA-mutant breast cancer."@en ;
  schema:url <https://onco.cc/drugs/inavolisib/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Inavolisib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q122766610> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Inavolisib> ;
  onco:status "approved" ;
  onco:modality "Small-molecule PI3Kα inhibitor and degrader" ;
  schema:alternateName "Itovebi" ;
  onco:approval "US 2024: PIK3CA-mutant HR+/HER2- advanced breast cancer with palbociclib and fulvestrant", "EU 2025: PIK3CA-mutant ER+/HER2- mBC with palbociclib + fulvestrant; 18 Jul 2025" ;
  onco:related <https://onco.cc/pairings/pi3k-pathway-plus-endocrine/>, <https://onco.cc/biomarkers/pik3ca-hotspot-mutation/> ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/hr-positive-metastatic-post-cdk46/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/pi3k-akt-mtor-inhibitors/> ;
  onco:targets <https://onco.cc/targets/pik3ca/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/> ;
  onco:terms <https://onco.cc/terms/hyperglycaemia/> ;
  onco:trials <https://onco.cc/trials/nct07287150/>, <https://onco.cc/trials/nct05646862/>, <https://onco.cc/trials/nct07368998/>, <https://onco.cc/trials/nct07405801/>, <https://onco.cc/trials/nct05894239/>, <https://onco.cc/trials/nct06790693/>, <https://onco.cc/trials/nct07054190/> .